Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XRx 225

Next Previous
X
Search
Drug Profile

XRx 225

Alternative Names: XRx-225

Latest Information Update: 11 Apr 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XORTX Pharma
  • Developer XORTX Therapeutics
  • Class Small molecules; Urologics
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic nephropathies

Most Recent Events

  • 07 Apr 2022 XORTX Pharma receives notification of intent to grant from the United States Patent Office for a patent covering xanthine oxidase inhibitors
  • 19 Oct 2021 Preclinical trials in Diabetic nephropathies in Canada before October 2021 (unspecified route) (XORTX Therapeutics pipeline, October 2021)
  • 01 Sep 2021 XORTX Pharma receives receipt of the patent grant “EPO National Stage of PCT International Application for Compositions and Methods for Treatment and Prevention of Hyperuricemia Related Health Consequences” by the European Patent Office

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top